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Abstract
Although multiple gene and protein expression have been extensively profiled in human pulmonary arterial hypertension
(PAH), the mechanism for the development and progression of pulmonary hypertension remains elusive. Analysis of the
global metabolomic heterogeneity within the pulmonary vascular system leads to a better understanding of disease
progression. Using a combination of high-throughput liquid-and-gas-chromatography-based mass spectrometry, we
showed unbiased metabolomic profiles of disrupted glycolysis, increased TCA cycle, and fatty acid metabolites with altered
oxidation pathways in the human PAH lung. The results suggest that PAH has specific metabolic pathways contributing to
increased ATP synthesis for the vascular remodeling process in severe pulmonary hypertension. These identified
metabolites may serve as potential biomarkers for the diagnosis of PAH. By profiling metabolomic alterations of the PAH
lung, we reveal new pathogenic mechanisms of PAH, opening an avenue of exploration for therapeutics that target
metabolic pathway alterations in the progression of PAH.
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Introduction
Pulmonary arterial hypertension (PAH) is a vascular disease
characterized by persistent precapillary pulmonary hypertension
(PH), leading to progressive right heart failure and premature
death [1]. Pulmonary hypertension can either be idiopathic
(sporadic-90%, familial-10%) or be the result of other conditions
such as connective tissue disease, congenital heart disease,
anorexigen use (dexfenfluramine), portal hypertension, and human
immunodeficiency virus [1]. However, the pathological mecha-
nisms underlying this condition remain elusive. Pulmonary artery
endothelial cell (PAEC) dysfunction and structural remodeling of
the pulmonary vessels are early features of PAH, characterized by
a hyperproliferative and anti-apoptotic diathesis within the
vascular wall of the resistant pulmonary arteries, leading to
vascular lumen occlusion, right ventricular failure, and death. It
has been reported that the PAH vascular remodeling process
includes proliferation and migration of pulmonary artery SMCs,
leading to medial hypertrophy and increased pulmonary vascular
resistance [2,3]. The local imbalance in vasoactive mediators as
well as shear stress promotes proliferation and hypertrophy of
endothelial and smooth muscle cells within pulmonary arterioles.
Early stages of vascular remodeling include medial hypertrophy
and hyperplasia, whereas the arterioles of patients with advanced
PAH are characterized by complex plexiform lesions resulting
from intimal hyperplasia [1,4–6]. The terminal stage of PAH is
characterized by a significant reduction in the cross sectional area
of the pulmonary vasculature leading to right ventricular failure - a
major factor for morbidity and mortality [4]. Recent evidence
shows that abnormal metabolic pathways may also play a
significant role in the development and progression of PAH [7].
A similar metabolic change has been identified as a feature of
malignant tumor transformation displaying characteristics similar
to hyperproliferative PAECs in PAH [8,9]. Moreover, it has been
shown that mitochondrial oxidative phosphorylation with glucose
uptake and utilization occurs in the pulmonary artery endothelium
of PAH patients [10], increasing the likelihood that metabolic
alterations in PAECs may be representative of disease develop-
ment. Increased hemoglobin levels have been found in the PAH
sample group without a history of diabetes or any other obvious
metabolic diseases, indicating the impairment of whole-body
glucose homeostasis in PAH [11–13]. In animal models with
chronic hypoxia induced PAH, vascular changes that are
characteristic of the disease have been directly linked to an
imbalance between glycolysis, glucose oxidation, and fatty acid
oxidation [14]. In addition, in vitro PA endothelial cell culture with
disruption of the BMPRII gene also showed significant metabo-
lomic changes [7]. These data from in vitro and animal models
suggest that molecular transcript and metabolic reprogramming
might play an important role in the molecular pathogenesis of the
early or developing stage of pulmonary hypertension. Here, we
provide direct evidence that metabolic heterogeneity exists in the
human lung with severe PAH. Our results show specific metabolic
pathways and genetic profiles with disrupted glycolysis, increased
TCA cycle and fatty acid metabolites with altered oxidation
pathways in the later stage of the human PAH lung, which suggest
that metabolic disruptions may underlie progression of severity for
PAH. These identified metabolites may serve as potential
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biomarkers for the diagnosis of PAH. In addition, by profiling
metabolomic alterations of the PAH lung, we reveal new
pathogenic mechanisms of severe PAH, which may differ from
the earlier stage of PAH, opening an avenue of exploration for
therapeutics that target metabolic pathway alterations in the
progression of PAH.
Materials and Methods
Patient population and Clinical Characteristics
Global biochemical profiles were determined in human lung
tissue and compared across 8 normal (47 +/2 15 years of age, 4
females) and 8 pulmonary arterial hypertension patients of PAH (5
idiopathic pulmonary hypertension (IPAH), 2 systemic lupus
(SLE)-PAH, 1 congenital heart disease (CHD)-PAH and Eisen-
menger’s syndrome-PAH;40 +/2 12 years of age, 5 females). All
patients provided written informed consent, in accordance with
the Declaration of Helsinki, for research protocols approved by
the University Health Network (UHN) Research Board
(#110932_AE). Eligibility criteria included end stage PAH
patients who went through lung transplantation. Lung samples
were obtained from the recipient lung at the time of lung
transplantation. Control lung samples were obtained from normal
tissue of cancer patients undergoing surgery lobectomy. The lung
samples were snap frozen in the operating room and stored in 2
80uC prior to sample analysis. The PAH patient cohort included
patients who had the WHO group l classification of pulmonary
hypertension according to the fifth World Symposium on
Pulmonary Hypertension [1]. Pulmonary hypertension was
diagnosed by right heart catheterization performed for clinical
care (with mean pulmonary artery pressures of 5669 mm Hg,
systolic pressure of 88616 mmHg, and diastolic pressure of
34614 mmHg). All patients provided written informed consent, in
accordance with the Declaration of Helsinki, for research
protocols approved by the institutional review boards of the
University Health Network (UHN).
Metabolomic profiling
Metabolomic analysis was performed as previously described
[7]. Briefly, samples were prepared using the automated MicroLab
STARH system (Hamilton Co, Reno, NV, USA). A recovery
standard was added prior to the first step in the extraction process
for quality control purposes. Samples were prepared using the
aqueous methanol extraction process to remove the protein
fraction while allowing maximum recovery of small molecules.
Metabolomic performance: The resulting extract was divided into four
fractions: one for analysis by UPLC/MS/MS (positive mode), one
for UPLC/MS/MS (negative mode), one for GC/MS, and one for
backup. Samples were placed briefly on a TurboVapH (Zymark) to
remove the organic solvent. Each sample was frozen and dried
under vacuum conditions. Samples were then prepared for the
appropriate instrument, either UPLC/MS/MS or GC/MS.
Ultrahigh performance liquid chromatography/Mass
Spectroscopy (UPLC/MS/MS)
The LC/MS portion of the platform was based on a Waters
ACQUITY ultra-performance liquid chromatography (UPLC)
and a Thermo-Finnigan linear trap quadrupole (LTQ) mass
spectrometer, which consisted of an electrospray ionization (ESI)
source and linear ion-trap (LIT) mass analyzer. The sample
extract was dried then reconstituted in acidic or basic LC-
compatible solvents, each of which contained 8 or more injection
standards at fixed concentrations to ensure injection and
chromatographic consistency. One aliquot was analyzed using
acidic positive ion optimized conditions and the other using basic
negative ion optimized conditions in two independent injections
using separate dedicated columns. Extracts reconstituted in acidic
conditions were gradient eluted using water and methanol
containing 0.1% formic acid, while the basic extracts, which also
used water/methanol, contained 6.5 mM ammonium bicarbon-
ate. The MS analysis alternated between MS and data-dependent
MS2 scans using dynamic exclusion. Raw data files were archived
and extracted as described below.
Gas chromatography/Mass Spectroscopy (GC/MS)
The samples destined for GC/MS analysis were re-dried under
vacuum desiccation for a minimum of 24 hours prior to being
derivatized under dried nitrogen using bistrimethyl-silyl-triflour-
oacetamide (BSTFA). The GC column was 5% phenyl and the
temperature ramp was from 40u to 300uC in a 16 minute period.
Samples were analyzed on a Thermo-Finnigan Trace DSQ fast-
scanning single-quadrupole mass spectrometer using electron
impact ionization. The instrument was tuned and calibrated for
mass resolution and mass accuracy on a daily basis. The
information output from the raw data files was automatically
extracted as discussed below.
Quality Control (QC)
Additional samples were included with each day’s analysis.
These samples included extracts of a pool created from a small
aliquot of the experimental samples and process blanks. QC
samples were spaced evenly among the injections and all
experimental samples were randomly distributed throughout the
run. A selection of QC compounds was added to every sample for
chromatographic alignment, including those being tested. These
compounds were carefully chosen so as to not interfere with the
measurement of the endogenous compounds.
Data extraction and compound identification
Raw data was extracted, peak-identified, and QC was processed
using Metabolon’s hardware and software. These systems are built
on a web-service platform utilizing Microsoft’s NET technologies,
which run on high-performance application servers and fiber-
channel storage arrays in clusters to provide active failover and
load-balancing. Compounds were identified by comparison to
library entries of purified standards or recurrent unknown entities.
More than 2400 commercially available purified standard
compounds have been acquired and registered into LIMS for
distribution to both the LC and GC platforms for determination of
their analytical characteristics.
Statistical Analysis
Missing values (if any) were assumed to be below the level of
detection. However, biochemicals that were detected in all samples
from one or more groups, but not in samples from other groups
were assumed to be near the lower limit of detection in the groups
in which they were not detected. In this case, the lowest detected
level of these biochemicals was imputed for samples in which that
biochemical was not detected. Following log transformation and
imputation with minimum observed values for each compound, a
Welch’s two-sample t-test was used to identify biochemicals that
differed significantly between experimental groups. Data analysis
was based on statistical significance (as well as those approaching
significance (0.05,p,0.10). Pathways were assigned for each
metabolite in order to examine the impact of an increased or
decreased metabolite on the overall pathway.
Metabolomic Heterogeneity of PAH
PLOS ONE | www.plosone.org 2 February 2014 | Volume 9 | Issue 2 | e88727
Transcriptomic analysis
Global profiles were determined in human lung tissue and
compared across normal and idiopathic pulmonary arterial
hypertension patients. The total RNA lung tissue analyses were
performed using Trizol extraction according to the manufacturer’s
instructions. Biotinylated cRNA were prepared according to the
standard Affymetrix protocol from 6 ug total RNA (Expression
Analysis). Following fragmentation, 10 ug of cRNA were hybrid-
ized for 16 hr at 45C on GeneChip Genome Array. GeneChips
were scanned using the HuGene-1_0-st-v1 GeneArray Scanner
G2500A. The data were analyzed with Partek Genomics Suite 6.6
using Affymetrix default analysis settings and global scaling as the
normalization method. The value definition was set up using
Partek Genomics Suite 6.6. Significantly changed genes were
determined using a minimum difference in expression of at least
200 arbitrary Affymetrix units, and P,0.01 by t-test with a false
discovery rate (FDR) of 2 fold. The database has been submitted to
NCBI/GEO and has been approved and assigned a GEO
accession number, GSE53408.
Immunoblotting
Protein concentrations were determined using the BCA protein
assay (Pierce, IL, USA). Equal amounts of the protein lysates were
separated by SDS-PAGE and transferred onto nitrocellulose
membranes. The membranes were incubated overnight at 4uC
with the following antibodies from AbcamR: anti-G6PC3 (1:1000);
anti-Lactate-Dehydrogenase-B (1:500); anti-ALDH18A1 (1:500).
After washing with TBS-Tween, the blots were incubated for
60 min at room temperature with horseradish peroxidase-conju-
gated antibodies, respectively: anti-rabbit antibody (1:15,000;
Sigma-Aldrich, St. Louis, MO). Signals from immunoreactive
bands were visualized by fluorography using an ECL reagent
(Pierce). The intensity of individual bands in the immunoblots was
quantified using the NIH Image program.
Immunohistochemistry
The sections of both PAH and normal lung tissue were fixed for
4 hours at room temperature with PBS made of 4% formalde-
hyde, permeabilized for 30 min in Triton X-100 (0.5% in PBS),
and incubated with 5% nonfat skim milk in PBS for 90 min.
Sections were incubated for 180 min at room temperature with
antibodies for anti-G6PC3 (1:1000); anti- Lactate-Dehydrogenase-
B (1:500); or anti- ALDH18A1 (1:500). The sections were then
incubated with biotinylated secondary antibody and visualized
with DAB. Stained cells and sections were visualized with the Zeiss
LSM 510 confocal microscope.
Results
PAH lung samples displayed broad changes in glucose and fatty
acid metabolism. Significant changes were also observed in the
TCA cycle compared to control lungs. We also analyzed the
microarray database and paid specific attention to enzyme related
genes that control and regulate affected metabolic pathways.
Profiling of gene array and metabolic analysis of the
severe PAH lung showed a significant alteration of
multiple interdependent metabolic pathways
PAH tissues exhibited a distinct metabolic signature in
comparison to the normal lung (NL), as shown in the principal
component analysis (PCA). Interestingly, the biochemical profiles
of PAH tissue showed a separation compared to control patients
(Figure 1a). In a simultaneous multiplexed mass spectrometric
quantification of several hundred small molecule metabolites in
the PAH lung, 376 small molecule metabolites were found in PAH
lung samples compared to normal lung samples (Figure 1b).
Among these molecules, ninety three biochemicals from the PAH
lung were significantly upregulated (n= 83) or down-regulated
(n= 10) compared with respective metabolites from the normal
samples (P-value ,0.05; FDR 1.1%). Thirty-one additional
metabolites showed a trend towards up-regulation (n= 23) or
down-regulation (n= 8). These multiple metabolic changes in
PAH reflect an important metabolic distinction of pulmonary
hypertension in the heat map that represents the none-supervised
hierarchical clustering (Figure 1c).Z-score plots show the 376
metabolites data that were normalized to the mean of the normal
samples (truncated at 25, Figure1d) [15]. Collectively, PAH
tissues were marked by a unique pattern of global metabolomic
heterogeneity compared to healthy subjects.
Abnormal cellular glycolysis in the severe PAH lung
Glucose metabolism plays an important role in the vascular
remodeling process in PAH, since glucose is critical for the
generation of cellular energy, nucleic acids, and biomass [13].
Therefore, we focused on glucose metabolites, gene encoding
enzymes, and enzyme proteins that were progressively altered in
glycolysis among PAH samples compared to the controls. PAH
patients exhibited higher levels of glucose, sorbitol, fructose, and
fructose-6-phosphate, suggesting the shuttling of glucose metabo-
lism towards the sorbitol pathway (Figure 2a). Although higher
levels of fructose 6-phosphate were observed in PAH samples,
multiple late-stage glycolytic intermediates including fructose 1,6-
bisphosphate, 3-phosphoglycerate, and phosphoenolpyruvate
(PEP) were reduced in these tissues, indicating a disruption of
glycolysis in PAH (Figure 2b). In conjunction with our
metabolomics study, we also performed a molecular analysis.
Gene microarray analysis showed that the gene encoding glucose
6-phosphatase subunit C3 (G6PC3), a key enzyme in the
homeostatic regulation of blood glucose levels, was significantly
decreased in the PAH lung (Figure 2c). G6P hydrolyzes glucose-
6-phosphate and results in the creation of a phosphate group and a
free glucose molecule. In agreement with findings from our
metabolomic and microarray analyses, protein analysis showed
that the expression of G6PC3 (38KD) was significantly decreased
in PAH (Figure 2d). Immunohistochemistry showed that G6PC3
was found in collagen fibers around pulmonary vascular smooth
muscle cells in the normal lung, and G6PC3 levels had decreased
in collagen fibers of the PAH lung. Moreover, increased levels of
fructose 6-phosphate in PAH lungs (Figure 2f) led us to believe
that altered levels of fructose 6-phosphate may be indicative of a
change in phosphofructokinase (PFK) activity. Indeed, our gene
array analysis showed that PFK, specifically the 6-phosphofructo-
2-kinase/fructose-2, 6-biphosphatase 2 (PFKFB2) gene, was
significantly expressed in PAH compared to the normal control
(Figure 2c). In addition, we found that the PAH lung had
significantly increased gene expression for lactate dehydrogenase B
(LDHB, Figure 2c&e), which catalyzes the interconversion of
pyruvate to lactate with concomitant interconversion of NADH to
NAD+ when oxygen is absent or in short supply. Increased levels
of PFKFB2 and LDHB plus deceased G6PC3 at both genetic and
protein levels may be the result of feedback mechanisms due to
disrupted glycolysis and excessive intracellular and extracellular
glucose levels. Together, these findings suggest that there is
reprogramming of glucose metabolism in the severe PAH lung,
leading to disrupted glucose uptake and altered glycolysis.
Changes in glucose metabolism may contribute to the pathology
Metabolomic Heterogeneity of PAH
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of the disease by promoting vascular cell proliferation and vascular
remodeling.
Increase of -oxidation in dicarboxylic fatty acids and up-
regulation of lipid oxidation in PAH
Dicarboxylic fatty acids are generated when the terminal methyl
group of a fatty acid is converted into a carboxyl group
(Figure 3a). The catabolism of fatty acids typically occurs via
b-oxidation in the peroxisomes and/or mitochondria under
normal conditions[16,17]. Our metabolon data showed a signif-
icant accumulation of dicarboxylic fatty acids, in particular,
tetradecanedioate, hexadecanedioate, and octadecanedioate in
PAH tissue, suggesting that the fatty acid metabolic pathway had
been altered to increase -oxidation in the smooth endoplasmic
reticulum in addition to b-oxidation in the peroxisome or
mitochondria of the PAH lung (Figure 3b). To explore this
finding further, we performed a gene array analysis and found that
the gene encoding aldehyde dehydrogenase 18 family, member
A1(ALDH18A1), a major enzyme in -oxidation, was significantly
over expressed in the PAH lung (p= 0.000187) (Figure 3c).
Accordingly, protein expression of ALDH was also increased in
the lung lysate (p = 0.04; Figure 3d). In addition, ALDH was
highly expressed in human smooth muscle cells and endothelial
cells (Figure 3e). Both metabolomical and genetic results indicate
that -oxidation may serve as the major oxidation pathway for
Figure 1. Metabolomic profiling of pulmonary hypertension. a), Principal component analysis (PCA) for metabolom PAH tissue exhibited a
distinct metabolic signature in comparison to NL. b), Statistical comparisons using Welch’s Two-Sample t-Test show significantly altered biochemicals
in PAH samples (N = 8) compared with biochemical profiling in normal samples (N = 8). Interestingly, the biochemical profiles of PAH tissue exhibited
higher levels of 93 altered metabolites compared with the normal lung (p#0.05). c), Heat map that represents the non-supervised hierarchical
clustering of 93 differential metabolites in PCA relative to normal sample data over eight PAH lungs (n = 8). Shades of light yellow/blue represent the
increase and decrease of a metabolite, respectively, relative to the median metabolite levels. d) z-score plots show the 376 metabolites data that were
normalized to the mean of the normal samples (truncated at 25).
doi:10.1371/journal.pone.0088727.g001
Metabolomic Heterogeneity of PAH
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Figure 2. Glycolysis is significantly upregulated in the PAH lung. a) In all graphs, data for normal lung are shown in green boxes and data for
the PAH lung are represented in pink boxes. Quantities are in arbitrary units specific to the internal standards for each quantified metabolite and
normalized to protein concentration (N= 8 for each box). PAH patient samples exhibited higher levels of glucose, sorbitol, fructose, and fructose 6-
phosphate. This metabolic disruption can contribute to the formation of advanced glycolytic end products that have been shown to directly
contribute to the severity of PAH. b) The classical glycolysis/pentose/energy pathways are shown. c)Three genes encoding G6PC3, PFKFB2, and LDHB
were significantly changed in PAH lung compared with NL, as shown in all graph) (G6PC3 (p = 8.54e205), PFKFB2 (p = 2.6e-04) and LDHB (p = 2.19e2
09). d) Western Blot analysis of G6PC3 (n = 4/each group) and e) LDHB expression in normal and PAH lungs (n = 4/each group). Lung lysate (20 ug per
lane) was loaded and immunoblotted with antibody against G6PC3 or LDHB and GAPDH (loading control). Consistent with a significant decrease of
G6PC3 and an increase of LDHB gene expression in PAH, protein expression for G6PC3 (39KD) was significantly decreased while LDH (37KD) was
significantly increased in PAH lungs compared with NL lungs. Densitometric analysis of G6PC3 and LDHB were normalized to the intensity of the
respective GAPDH band. Data are expressed as mean6SD (n = 4). *P,0.05 versus NL. f), Representative images of G6PC3 positive immunostaining in
the collagen fibers of pulmonary vascular tissue, which was decreased in PAH. Increased LDHB positive staining was found in pulmonary vascular
smooth muscle tissue in the PAH lung (bar = 1:400).
doi:10.1371/journal.pone.0088727.g002
Metabolomic Heterogeneity of PAH
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fatty acids when b-oxidation is no longer sufficient to supply ATP
as a critical source of energy for the vascular remodeling process in
PAH (Figure 3f).
In PAH tissue, there was also an accumulation of adrenate (a
pro-thrombotic lipid that can cause obstructions). Long- and
medium-chain free fatty acid products (including caproate,
Figure 3. Mitochondrial b–Oxidation Disturbance. a), fatty acid –oxidation for dicarboxylic acid production. b) In PAH tissue, there was a
significant accumulation of the dicarboxylic fatty acids tetradecanedioate, hexadecanedioate, and octadecanedioate. An accumulation of adrenate (a
pro-thrombotic lipid) can cause obstructions that may serve as a biomarker for the disorder. These changes in the lipid profile potentially reflect
altered mitochondrial fatty acid oxidation. c), Gene array analysis showed that the gene encoding aldehyde dehydrogenase 18 family, member
A1(ALDH18A1) was significantly increased in PAH (p= 1.87e4). d) Western blot analysis of ALDH1L1 expression in normal and PAH lungs. Lung lysate
(20 ug per lane) was loaded and immunoblotted with antibody against ALDH1L1 and GAPDH (loading control). Protein expression of ALDH1L1
(40KD) was slightly increased in PAH lungs compared with NL lungs. Densitometric analysis of ALDH was normalized to the intensity of the respective
GAPDH band. Data are expressed as mean6 SD (n = 4). *P,0.05 versus NL. e) ALDH positive immunostaining in pulmonary vascular smooth muscle
cells and endothelial cells in pulmonary vessel of the PAH lung. Representative micrographs of immunostaining of PAH lung sections with anti–ALDH
in the pulmonary vascular endothelial cells (bar = 1:400). f) Dicarboxylic fatty acids are generated when the terminal methyl group of a fatty acid is
converted into a carboxyl group and are often indicative of alterations in - v oxidation. The catabolism of fatty acids typically occurs via b-oxidation in
the peroxisomes and/or mitochondria. In contrast, fatty acid -oxidation occurs in the smooth endoplasmic reticulum and often serves as a rescue
pathway for pathological conditions such as PAH when b-oxidation is disrupted.
doi:10.1371/journal.pone.0088727.g003
Metabolomic Heterogeneity of PAH
PLOS ONE | www.plosone.org 6 February 2014 | Volume 9 | Issue 2 | e88727
caprylate, myristate, and palmitoleate) accumulated in PAH tissues
compared to control lung (Figure 4a). The increased lipid profile
in PAH potentially reflects mitochondrial fatty acid oxidation. In
correlation with the mebobolomics finding, we found that four
genes that encode the enzymes fatty acetyl CoA L1 (ACSL1), Acyl-
CoA dehydrogenases (ACADM), Acetyl –Coa Acetyl transferase1
(ACAT1), and Acetyl CoA Carboxylase (ACACA) were all
significantly highly expressed (Figure 4b).
Intermediate and enzyme encoded genes were
significantly increased in the TCA cycle
In the TCA cycle, most intermediates were significantly
increased in the PAH lung, including citrate and cis-aconitate
(Figure 5a). Aconitase is the enzyme that catalyzes the formation
of cis-aconitate from citrate. One of the two isoforms of aconitase
is the iron2responsive element binding protein 1(Aco1) in the
cytoplasm. Genetic analysis showed that Aco1 was more highly
expressed in PAH (Figure 5b). The second isoform of aconitase,
iron2responsive element binding protein 2 (IREB2), helps to
control iron metabolism by binding to mRNA to repress
translation or degradation. IREB-2 was also significantly increased
Figure 4. Carnitine metabolism and fatty acid oxidation are significantly increased in the PAH lung. Multiple carnitine metabolites that
flow into the fatty acid oxidation pathway are shown. Gene array shows that expression of genes coding for the key enzymes that catalyze particular
steps in the pathway are significant increased, specifically Fatty Acetyl CoA synthase L1 (ACSL1); Acyl-CoA dehydrogenases isoforms M (ACADM;
Acetyl –Coa Acetyl transferase 1 (ACAT1); Acetyl CoA Carboxylase isoform A (ACACA) short chain, medium chain, short/branched chain, and very long
chain; and malonyl CoA decarboxylase. Metabolic intermediates for which significant differences were detected between NL and PAH are shown with
a red frame (p,0.05); N = 8 for each box).
doi:10.1371/journal.pone.0088727.g004
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in the PAH lung (Figure 5b), suggesting increased aconitase
enzymatic activity may play a significant role in the conversion of
citrate to isocitrate
Other TCA metabolites, including succinate and succinyl
carnitine, were also elevated in PAH (Figure 5a). In correlation
with increased metabolites, SUCLA2, the gene encoding succinate
–CoA ligase, was significantly highly expressed (p= 1.59e-7,
Figure 5b). In addition, the gene encoding fumarate hydratase
(FH, data not shown) was also significantly highly expressed in the
PAH lung. Our results show higher gene expression of isocitrate
dehydrogenase1 (IDH1, p= 4.96e-9) in the PAH lung, suggesting
that cytoplasmic IDH plays a significant role in cytoplasmic
NADPH production. Together, these findings suggest that
increased metabolites and related gene expression in the TCA
cycle are altered in PAH patients and may potentially reflect
abnormalities in mitochondrial function.
Discussion
This study was conducted to identify differences in molecular
and biochemical profiles of lung tissue harvested from normal
lungs and lungs from patients with advanced PAH in an effort to
better understand the metabolic changes that occur in the
progression of early to severe PAH. Various pathological changes
occurring in pulmonary arteries, specifically in the terminal small
arteries, can contribute to the development and progression of
PAH [18]. Understanding how changes in gene and protein
expression of altered metabolic pathways contribute to the
pathogenesis of PAH may lead to the development of new
Figure 5. Upregulated TCA cycle in PAH lung samples. a) Data for metabolic intermediates in the normal lung are shown in green boxes and
data for PAH are represented in pink boxes. PAH patients exhibited higher levels of citrate, cis-aconitate, succinate, and succinyl carnitine. b) The
pathway for the tricarboxylic acid (TCA) cycle, the metabolic pathway for glucose oxidation in the mitochondria, is shown. Upregulated metabolic
intermediates (citrate, cis-aconitase, succinyl-CoA, and succinate) are shown in red. c) Analysis of gene expression for key enzymes of the TCA cycle.
Data from normal lung are represented in blue and data from PAH lung are shown in green. Aco1 (p = 1.068610-3) andIREB-2were upregulated in the
PAH lung sample (p = 1.59e-07), as well as IDH1 for converting isocitrate to a-ketoglutarate with the interconversion of NADP+ to NADPH
(p= 4.96610-9). SUCLA-2, which is one of two genes that encode succinate-CoA ligase for the conversion of succinyl-CoA to succinate with an
interconversion of GDP to GTP, was upregulated in PAH patients compared to the normal control (p = 4.17610-8).
doi:10.1371/journal.pone.0088727.g005
Metabolomic Heterogeneity of PAH
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biomarkers and novel therapeutics that target these pathways. Our
study of PAH metabolism primarily focused on pathways that,
when altered, can lead to the aberrant production or consumption
of essential biomolecules such as glucose, amino acids, nucleotides,
and lipids in severe PAH. Most importantly, we have shown that
there is disrupted glycolysis in the cytoplasm, altered glucose
metabolism through the TCA pathway in the mitochondria, and
altered fatty acid metabolism through -oxidation in the smooth
endoplasmic reticulum (ER) in addition to b-oxidation in the
mitochondria in the progression of severe PAH.
Interestingly, our results have shown that there is reduced
glycolysis in the PAH lung compared to normal control, which is
contrary to several previous studies [19–21], showing increased
glycolysis as a significant characteristic of proliferating cells in
PAH. The discrepancy between our findings to previous studies
may be due to our usage of lung samples with severe PAH rather
than lung samples with early or developing of PAH from previous
works. Our results describe metabolic alterations that occur in the
progression of PAH from the early to severe stage, where
alterations in glucose metabolism through downregulation of
glycolysis play an important role, while previous works likely focus
on the metabolic alterations that occur in the initial onset or
developing stage of PAH. Previous studies, based on hypoxia-
induced PH in a relatively earlier/or developing stage of PH
animal model (2–3 wks hypoxia) describes that the upregulation of
hypoxia-induced factor (HIF-1a), in combination with HIF-1b,
activates over 100 genes involved in metabolism [20]. In
particular, there is increased glucose uptake via GLUT1 and
GLUT3 as well as inhibition of the pyruvate dehydrogenase
complex (PDC) by pyruvate dehydrogenase kinase (PDK) that
normally oxidizes pyruvate to acetyl-CoA for the Krebs cycle
[19,21]. Other studies have shown that vascular endothelial
proliferation in IPAH lesions displays pathological alterations that
resemble characteristics of growing tumor cells in cancer [22].
These cells are characterized by the ‘‘Warburg effect’’, as
hyperproliferative tumor cells under hypoxic conditions use
aerobic glycolysis with resultant changes in its mitochondrial
redox state to escape apoptosis in the developing stage of the PH
[9,21,23]. Results from previous studies that suggest for increased
glycolysis had worked with experimental models of PH at the
relatively early stage, such as in vitro studies using smooth muscle
cells from animals exposed to 2–3 weeks of hypoxia or in vitro
human pulmonary microvascular endothelial cells s(HMVEC-L)
transfected with a BMPRII mutation [7]. In several of these
studies, PH was induced by experimental measures and studies
focused solely on one cell type, which would ignore possible cell-
cell interactions that occur in the vascular remodeling process. In
contrast to previous studies, our results were obtained from the
severe human PAH lung rather than from animal models, which
may be the underlying reason for the observation of reduced
glycolysis. It remains elusive whether changes in metabolic
pathways, for example, the rate of glycolysis, can reflect different
stages in the progression of human pulmonary arterial hyperten-
sion. If so, such changes in glycolytic intermediates could serve as
potential biomarkers for the diagnosis and prognosis of the disease.
Our results suggest that there is a switch of energy usage with an
overall decrease of glucose metabolism characterized by down
regulated glycolysis, as well as excessive intracellular and
extracellular glucose levels in the severe PAH lung. In addition,
although glucose metabolism appears to be disrupted, excess
glucose accumulation as a result of reduced glycolysis leads to the
production of sorbitol, and, consequently, the potential formation
of glycation products that can generate free radicals and trigger
tissue damage [24]. Lactate levels did not significantly change,
suggesting that excess glucose is used instead by the sorbitol
pathway or pentose phosphate pathway. Based on our metabo-
lomics and microarray data, we tentatively suggest that the human
lung with advanced PAH does not produce high levels of lactate
that are typically a signature trait of the Warburg effect in the
earlier developing stages of PAH. Further experimentation based
on the radioactive targeted approach [14] on the human PAH
lung will clarify this issue.
Our study suggests that the process of vascular remodeling in
PAH involves alterations in glycolysis in multiple cells, limited not
only to SMCs but also includes endothelial cells and other tissues
such as collagen fibers around the peri-vascular tissue. Lung
samples from PAH patients exhibited higher levels of glucose,
sorbitol, and fructose. By gene array and immunostaining, we
showed that genes in vascular smooth muscle cells encoding the
key enzymes for glycolysis, such as LDH-B, were significantly
increased, whereas genetic expression of other key enzymes in the
glycolytic pathway, specifically glucose-6-phosphatase subunit C3
(G6PC3) was significantly downregulated. Glucose-6-phosphate
(G6P), a key rate-limiting metabolite in normal glycolysis and a
substrate for G6PC3, can enter many pathways, including
gluconeogenesis to produce glucose [25], glycogenesis for storing
glucose, anaerobic glycolysis [26] to convert to pyruvate, or
entrance to the pentose phosphate pathway for generating ribose-
5-phsophate (R5P) for the synthesis of nucleotides and erythrose-4-
phosphate (E4P) for the biosynthesis of aromatic amino acids. In
particular, the enzyme glucose-6-phosphatase plays a major role in
the gluconeogenesis process of dephosphorylating glucose-6-
phsophate to generate glucose [27]. Our studies showed that
G6PC3 was down-regulated in PAH at both the transcriptional
and translational level (Fig 2c,d,f), suggesting that decreased
expression of G6PC3 may be due to a decrease of G6P as a result
of glucose being shuttled towards the sorbitol fructose pathway.
Despite a decrease in glycolytic key intermediates and enzymes,
PFKFB2, an enzyme responsible for irreversibly converting
fructose-6-phosphate (F6P) to fructose-1,6-bisphosphate (1,6-FBP)
in the committed step of glycolysis was increased, perhaps in
response to increased F6P levels, yet there was a decrease in the
product fructose 1,6-bisphosphate in PAH lungs. An increase in
PFKFB2 may be a feedback mechanism of decreased fructose 1,6-
bisphosphate in an attempt to restore normal glycolysis, although
protein levels of PFKB2 did not display significant changes. Our
results also showed that the gene encoding lactate dehydrogenase
B (LDHB) was highly expressed in the PAH lung. Further studies
will be conducted to determine the specific roles of PFKFB2 and
LDHB, and whether its upregulation is significant in promoting
glycolysis as a countering mechanism for attenuating PAH.
With the understanding that fatty acid signaling is important
during cholesterol metabolism and that the alteration of glucose
and fatty acid signaling is a key factor for vascular remodeling in
the development of PAH, we investigated the level of intermediate
metabolites and expression of genes and enzymes of fatty acid
metabolism in PAH lungs. Our results implied increased fatty acid
metabolism due to increased expression of genes for beta
oxidation, such as Acyl-CoA dehydrogenases isoforms M
(ACADM) and Acetyl–Coa Acetyl transferase1 (ACAT1), suggest
that fatty acid metabolism may play an important role in human
PAH by switching the fuel of existing mitochondrial oxidative
metabolism from glucose to fatty acids. Increased vascular
remodeling in PAH can be achieved by increased fatty acid
metabolism as well as by increased -dicarboxylic fatty acid
oxidation in the ER. Upregulation of omega oxidation, charac-
terized by increased end products such as tetradecanedioate,
hexadecanedioate, and octadecanedioate may compensate for the
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insufficient glucose metabolism. Fatty acid oxidation and glucose
oxidation both produce mitochondrial acetyl-CoA. As a result, the
rate of glucose oxidation has a direct and reciprocal effect on the
rate of fatty acid oxidation and vice versa through the Randle
cycle. The stimulation of fatty acid oxidation can replace glucose
oxidation to produce high-energy cofactors at a more efficient rate.
Therefore, our results suggest that vascular remodeling may rely
primarily on fatty acid oxidation rather than on glycolysis, which is
supported by an animal PAH model that showed attenuation of
PAH upon inhibiting fatty acid oxidation due to a lack of malonyl-
coenzyme A (MCD) expression [14]. Replacement of glucose
oxidation with fatty acid oxidation also allows for increased
production of ATP and NADPH in order to sustain rapidly
dividing cells. Analyzing change in the level of intermediate
metabolites and studying the regulation of specific enzymes in
glycolysis, TCA, and fatty acid oxidation may provide a more
accurate outline of the metabolic mechanisms in PAH. Ultimately,
our result of increased fatty acid oxidation in PAH suggests that
fatty acid inhibitors such as etomoxir and ranolazine trimetazidine
may have beneficial effects in attenuating PAH.
The TCA cycle is the common pathway for the oxidation of
carbohydrates, lipids, and selective amino acids. Our results
concordantly showed that there is increased citrate and cis-
aconitate at the beginning of the citric acid cycle, suggesting that
there is an upregulation of the TCA cycle. As a result, metabolic
intermediates of the TCA cycle are continually transported to the
cytoplasm for increased fatty acid synthesis to produce energy for
the vascular remodeling process. To support our speculation that
metabolic changes in the TCA cycle contribute towards greater
energy production, we also found increased conversion of succinyl-
CoA to succinate, a process that normally produces high-energy
GTP due to phosphorylation of GDP. In addition, the enzyme
IDH1 is normally found in the cytoplasm and plays a key role in
beta-oxidation of fatty acids in peroxisomes [27]. Increased genetic
expression of IDH1 supports our results that there is increased
beta-oxidation and that substrates for fatty acid oxidation are
being shuttled towards omega-oxidation in the severe PAH lung.
Our results also showed increased genetic expression of iron-
responsive element binding protein (IREB-2), a cytoplasmic form
of the enzyme aconitase that mediates the conversion of citrate to
cis-aconitate. Our findings suggest that IREB-2 may be respon-
sible for increased metabolic intermediates that were observed
downstream of citrate in the TCA cycle.
Taken together, we explored the metabolome of PAH and
characterized metabolomic signatures, which in the context of
other molecular alterations may lead to a complete understanding
of disease progression. Specifically, we identified that disrupted
glycolysis in conjunction with increased fatty acid metabolism and
an altered -oxidation pathway directly regulates pathological
vascular remodeling in the advanced stage of PH by means of
transcriptional control of its regulatory enzymes. Fatty acid
oxidation is a more efficient process compared to glycolysis for
ATP production and would be the more ideal metabolic pathway
for supplying energy for further vascular remodeling after
plexiform lesions have developed. Identifying altered metabolites
of glucose and fatty acid metabolism is ideal, as these metabolites
may serve as potential biomarkers for diagnosing PAH, for making
more accurate prognoses of the disease, and for monitoring PAH
progression. Our results hold clinical significance for developing a
combination of therapeutic techniques. With a better understand-
ing of the metabolomic changes that occur during PAH, metabolic
modulation therapy can be further developed to control vascular
remodeling and cell proliferation for the treatment of PAH in its
advanced stage. By reconsidering treatment strategies for PAH, we
suggest that PAH can be attenuated by inhibiting glycolysis at the
early stage of the disease and by inhibiting fatty acid oxidation
towards the advanced stage of the disease. These metabolic
interventions may open a new avenue of therapeutics that is less
invasive for the treatment of PAH.
Supporting Information
Figure S1 Representative image of hematoxylin-eosin
staining of lung from both control and PAH patients. The
control lung tissue from marginal zone of lung from tumor related
lobectomy. Histological images of control shows that the control
lung tissue is morphologically normal (bar ratio = 1:100).
(TIF)
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